BSLN — Basilea Pharmaceutica AG, Allschwil Share News
0.000.00%
Last trade - 00:00- CH₣888.06m
- CH₣785.65m
- CH₣232.38m
Brief: Basilea Receives USD 25 Million Funding Under Barda Agreement To Continue To Advance Novel Antifungals Fosmanogepix And Bal2062
Brief: Basilea Pharmaceutica H1 Revenue Up At CHF 104.0 Mln
Brief: Basilea To In-License Novel Clinical Phase 3-Ready Oral Antibiotic
Brief: Basilea Initiates Phase 3 Study With Antifungal Fosmanogepix In Invasive Mold Infections
Brief: Basilea Receives USD 39 Mln Funding
Brief: Basilea Announces Commercial Availability Of Antibiotic In The United States
Brief: Cresemba Sales In Japan Trigger Second Milestone Payment From Asahi Kasei Pharma To Basilea
Swiss stocks - Factors to watch on April 16
Swiss stocks - Factors to watch on March 14
Brief: Basilea Pharmaceutica Gets USD 2.5 Mln Milestone Payment For Cresemba Sales In Asia Pacific And China
Brief: Basilea Pharmaceutica Expects Revenue To Rise 5.5% To CHF 220 Mln in 2025
Brief: Basilea Pharmaceutica FY Operating Income CHF 61.2 Million
Swiss stocks - Factors to watch on February 18
Brief: Basilea: Sales Growth For Cresemba And Zevtera Trigger Further Milestone Payments To Basilea
Brief: Basilea Announces Agreement With Innoviva Specialty Therapeutics For Commercialization Of Zevtera In The United States
Corrected: BRIEF-Basilea Pharmaceutica H1 Operating Income CHF 9.3 Million
Brief: Basilea Pharmaceutica AG Allschwil - Partners Oncology Drug Candidate Lisavanbulin With Glioblastoma Foundation
Newscasts - Europe Today: Euro zone business activity returns to growth in March
European stocks rise ahead of inflation data; Basilea shines (updated)